- Home
- RVI vs OMER Comparison
RVI vs OMER Comparison
Compare RVI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVI | OMER |
|---|---|---|
| Founded | N/A | 1994 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.0M | 772.8M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RVI | OMER |
|---|---|---|
| Price | $33.03 | $14.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 407.7K | ★ 1.1M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.21 | $2.95 |
| 52 Week High | $36.06 | $17.65 |
Technical Indicators
Market Signals| Indicator | RVI | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 72.00 |
| Support Level | $24.75 | $10.82 |
| Resistance Level | $35.53 | $17.65 |
| Average True Range (ATR) | 2.05 | 0.65 |
| MACD | 0.62 | 0.19 |
| Stochastic Oscillator | 77.01 | 91.22 |
Price Performance
Historical ComparisonAbout RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The Fund's investment objective is to seek long-term capital appreciation.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.